Importer of Controlled Substances Notice of Application, 55583 [E9-25862]

Download as PDF 55583 Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices In light of these circumstances, the Commission has determined as follows: (a) The public may submit comments on remedy, the public interest, and bonding until November 2, 2009. (b) The parties and the public may reply to any submissions on remedy, the public interest, and bonding until November 9, 2009. (c) The parties’ schedule for briefing on any issues related to violation is unaffected by this extension. This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and under sections 210.50 of the Commission’s Rules of Practice and Procedure (19 CFR 210.50). Issued: October 23, 2009. By order of the Commission. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E9–26019 Filed 10–27–09; 8:45 am] Commerce on or before November 17, 2009.) 6. Inv. Nos. 701–TA–473 and 731– TA–1173 (Preliminary) (Certain Sodium and Potassium Phosphate Salts from China)—briefing and vote. (The Commission is currently scheduled to transmit its determinations to the Secretary of Commerce on or before November 9, 2009; Commissioners’ opinions are currently scheduled to be transmitted to the Secretary of Commerce on or before November 17, 2009.) 7. Outstanding action jackets: none. In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting. BILLING CODE 7020–02–P By order of the Commission. Issued: October 26, 2009. William R. Bishop, Hearings and Meetings Coordinator. [FR Doc. E9–26104 Filed 10–26–09; 4:15 pm] INTERNATIONAL TRADE COMMISSION BILLING CODE 7020–02–P [USITC SE–09–029] DEPARTMENT OF JUSTICE erowe on DSK5CLS3C1PROD with NOTICES Government in the Sunshine Act Meeting Notice Drug Enforcement Administration AGENCY HOLDING THE MEETING: United States International Trade Commission. TIME AND DATE: November 6, 2009 at 11 a.m. PLACE: Room 101, 500 E Street, SW., Washington, DC 20436, Telephone: (202) 205–2000. STATUS: Open to the public. MATTERS TO BE CONSIDERED: 1. Agenda for future meetings: none. 2. Minutes. 3. Ratification List. 4. Inv. Nos. 701–TA–470–471 and 731–TA–1169–1170 (Preliminary) (Certain Coated Paper Suitable for HighQuality Print Graphics Using Sheet-Fed Presses from China and Indonesia)— briefing and vote. (The Commission is currently scheduled to transmit its determinations to the Secretary of Commerce on or before November 9, 2009; Commissioners’ opinions are currently scheduled to be transmitted to the Secretary of Commerce on or before November 17, 2009.) 5. Inv. Nos. 701–TA–472 and 731– TA–1171–1172 (Preliminary) (Certain Standard Steel Fasteners from China and Taiwan)—briefing and vote. (The Commission is currently scheduled to transmit its determinations to the Secretary of Commerce on or before November 9, 2009; Commissioners’ opinions are currently scheduled to be transmitted to the Secretary of VerDate Nov<24>2008 15:34 Oct 27, 2009 Jkt 220001 Importer of Controlled Substances Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on August 27, 2009, Formulation Technologies LLC., 11400 Burnet Road, Suite 4010, Austin, Texas 78758, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for analytical characterization, secondary packaging, and for distribution to clinical trial sites. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 27, 2009. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: October 20, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25862 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application This is notice that on July 9, 2009, Cody Laboratories Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414–9321, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Drug Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). Schedule II II The company plans to import narcotic raw materials for manufacturing and further distribution to its customers. The company is registered with DEA as a manufacturer of several controlled substances that are manufactured from raw opium, poppy straw, and concentrate of poppy straw. E:\FR\FM\28OCN1.SGM 28OCN1

Agencies

[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Page 55583]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25862]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II, and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on August 27, 2009, Formulation 
Technologies LLC., 11400 Burnet Road, Suite 4010, Austin, Texas 78758, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as an importer of Fentanyl (9801), a basic class 
of controlled substance listed in schedule II.
    The company plans to import the listed controlled substance for 
analytical characterization, secondary packaging, and for distribution 
to clinical trial sites.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed 
no later than November 27, 2009.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substances in schedule I or II are, and will continue to be, required 
to demonstrate to the Deputy Assistant Administrator, Office of 
Diversion Control, Drug Enforcement Administration, that the 
requirements for such registration pursuant to 21 U.S.C. 958(a); 21 
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are 
satisfied.

    Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-25862 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.